1 min read Health UCB Reports Positive Phase 3 Results for Fenfluramine in CDD Editorial 8 December, 2025 UCB, a global biopharmaceutical company, announced significant findings from its GEMZ phase 3 study,...Read More
3 min read Science UCB Unveils 26 Research Findings at International Epilepsy Congress Editorial 29 August, 2025 UCB, a prominent global biopharmaceutical company, is set to present a total of **26...Read More
